Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program
Recursion official investor newsroom · 行業原文收錄 · 來源發佈：Wed Aug 05 2026 10:30:38 GMT+0000 (Coordinated Universal Time) · 本站收錄：Thu Oct 08 2026 09:07:50 GMT+0000 (Coordinated Universal Time)
已保存的原文節選
Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program August 5, 2026 at 6:30 AM EDT PDF Version Genentech advanced the collaboration's first neuroscience target into a joint early discovery program, providing early evidence that Recursion's platform can generate novel, biologically validated targets for drug discovery REC-4881
以上為帶出處的原文節選，完整內容請閱讀原始鏈接。自動收錄與主題分類不等於事實核驗。